Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Newsletter Article
|
Press Release: Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)Dow Jones Institutional News, 2024Copyright Dow Jones & Company Inc. May 6, 2024Digital Resources/Online E-Resources |
|
2 |
Material Type: Newsletter Article
|
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)Business Wire, 2024Copyright Business Wire 2024Digital Resources/Online E-Resources |
|
3 |
Material Type: Newsletter Article
|
Tenaya Therapeutics (TNYA: $4.54) falls 3.0%; -14c [3.0%]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 7, 2024Digital Resources/Online E-Resources |
|
4 |
Material Type: Newsletter Article
|
Tenaya Therapeutics (TNYA: $4.68) rises 1.3% on increasing volatility, hits 29-day high; +6c [1.3%]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 4, 2024Digital Resources/Online E-Resources |
|
5 |
Material Type: Newsletter Article
|
Weekly: Tenaya Therapeutics (TNYA: $4.68) jumps 9% - outperforming 95% of stocks; +37c [8.6%]News Bites US - NASDAQ, 2024Copyright News Bites Pty Ltd May 6, 2024Digital Resources/Online E-Resources |